From: Efficacy and safety of caspofungin for patients with hepatic insufficiency
Group | Time | albumin g/L | ALT U/L | AST U/L | ALP U/L | GGT U/L | TBIL U/L | Scr mmol/L | eGFR ml/min |
---|---|---|---|---|---|---|---|---|---|
A | D0 D1 D7 X2 P | 33.7 (29–37) 33.3 (30–35) 31.4 (29–33) 5.79 0.06 | 28.0 (13–60) 24.5 (12–71) 21.5 (12–41) 2.80 0.25 | 20.0 (16–40) 20.5 (13–38) 22.5 (13–40.) 3.98 0.14 | 85.0 (72–133) 85.5 (60–124) 80.0 (63–108) 9.41 0.01 | 68.0 (31–191) 67.0 (29–172)* 52.0 (22–100)*# 14.00 0.01 | 9.0 (5–13) 8.8 (5–12) 7.9 (6–11) 1.17 0.56 | 62.9 (53–85) 60.9 (48–86) 61.0 (45–71) 6.39 0.04 | 78.8 (52–96) 87.7 (60–107) 94.9 (63–120) 5.43 0.06 |
B | D0 D1 D7 X2 P | 30.0 (28–32) 29.3 (26–32) 29.9 (28–32) 1.69 0.43 | 37.5 (16–80) 36.0 (12–71) 27.5 (14–59) 1.922 0.382 | 48.5 (27–84) 45.5 (23–99) 60.1 (25–86) 0.75 0.69 | 115.5 (68–147) 114.5 (70–154) 112.0 (90–209) 0.14 0.93 | 83.0 (29–165) 88.0 (34–153) 92.5 (37–143) 2.02 0.37 | 21.1 (10–42) 13.8 (8–40) 18.2 (8–36) 3.32 0.21 | 68.7 (56–100) 77.0 (50–106) 81.8 (58–112) 0.39 0.82 | 81.6 (46–106) 79.4 (45`104) 77.4 (37–98) 0.2 0.91 |
C | D0 D1 D7 X2 P | 30.6 (25–34) 30.0 (27–35) 31.0 (27–34) 0.22 0.89 | 21.0 (16–32) 22.0 (14–32) 17.0 (10–41) 0.456 0.796 | 48.0 (28–85) 44.0 (30–65) 55.0 (33–117) 2.63 0.27 | 88.0 (71–171) 77.0 (67–157) 86.0 (68–153) 5.52 0.06 | 37.0 (25–85) 37.0 (24–60) 46.0 (23–66) 7.18 0.03 | 163.0 (51–324) 156.0 (67–276) 162.0 (62–308) 0.65 0.72 | 89.0 (54–146) 83.4 (62–168) 79.9 (64–142) 0.78 0.68 | 69.6 (30–91) 69.7 (32–97) 65.0 (36–86) 1.00 0.61 |